Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data
Open Access
- 27 June 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (6), e67980
- https://doi.org/10.1371/journal.pone.0067980
Abstract
A major goal of cancer genome sequencing is to identify mutations or other somatic alterations that can be targeted by selective and specific drugs. dGene is an annotation tool designed to rapidly identify genes belonging to one of ten druggable classes that are frequently targeted in cancer drug development. These classes were comprehensively populated by combining and manually curating data from multiple specialized and general databases. dGene was used by The Cancer Genome Atlas squamous cell lung cancer project, and here we further demonstrate its utility using recently released breast cancer genome sequencing data. dGene is designed to be usable by any cancer researcher without the need for support from a bioinformatics specialist. A full description of dGene and options for its implementation are provided here.Keywords
This publication has 25 references indexed in Scilit:
- Whole-genome analysis informs breast cancer response to aromatase inhibitionNature, 2012
- Expression Profiling of the Ovarian Surface Kinome Reveals Candidate Genes for Early Neoplastic ChangesTranslational Oncology, 2009
- Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple MyelomaThe Journal of Immunology, 2009
- Genetic Variation in the Chromosome 17q23 Amplicon and Breast Cancer RiskCancer Epidemiology, Biomarkers & Prevention, 2009
- Protein tyrosine phosphatases: from genes, to function, to diseaseNature Reviews Molecular Cell Biology, 2006
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- The druggable genome: an updateDrug Discovery Today, 2005
- Coexpression of insulin receptor-related receptor and insulin-like growth factor 1 receptor correlates with enhanced apoptosis and dedifferentiation in human neuroblastomas.2003
- The Protein Kinase Complement of the Human GenomeScience, 2002
- TPIP: a novel phosphoinositide 3-phosphataseBiochemical Journal, 2001